CryoLife to Present at 2014 RBC Capital Markets' Global Healthcare Conference - myFOXnepa.com

CryoLife to Present at 2014 RBC Capital Markets' Global Healthcare Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE CryoLife, Inc.

ATLANTA, Feb. 18, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at The New York Palace Hotel in New York City.

A live webcast of the Company's presentation is scheduled to begin at 10:00 a.m. ET and will feature an overview of the company by Steven G. Anderson, president and chief executive officer, followed by a question and answer session.  

The live webcast can be accessed through CryoLife's website, www.cryolife.com, on the Investor Relations page.  An archived copy of the webcast will be available for 90 days on the same website.

About CryoLife

CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries.  It operates throughout the U.S. and internationally.  CryoLife manufactures and distributes BioGlue® Surgical Adhesive, an FDA approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  CryoLife and its subsidiary Hemosphere, Inc. market the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in Europe and other select international countries.  CryoLife's BioFoam® Surgical Matrix is CE marked in Europe for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects.

For additional information about the company, visit CryoLife's website: 
http://www.cryolife.com.

Contacts:

CryoLife       

D. Ashley Lee                                                

Executive Vice President, Chief Financial Officer

and Chief Operating Officer                                                

Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

©2012 PR Newswire. All Rights Reserved.